Meixi Hao, Ying Zhou, Sijia Chen, Yu Jin, Xiuqi Li, Lingjing Xue, Mingxuan Shen, Weishuo Li, Can Zhang
Due to multidimensional complexity of solid tumor, development of rational T-cell combinations and corresponding formulations is still challenging. Herein, a triple combination of T cells are developed with Indoleamine 2,3-dioxygenase inhibitors (IDOi) and Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). To maximize synergism, a spatiotemporally controlled T-cell engineering technology to formulate triple drugs into one cell therapeutic, is established. Specifically, a sequentially responsive core-shell nanoparticle (SRN) encapsulating IDOi and CDK4/6i is anchored onto T cells...
April 17, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)